Merus (NASDAQ:MRUS) Expected to Post Quarterly Sales of $10.64 Million

Wall Street brokerages expect Merus (NASDAQ:MRUSGet Rating) to report sales of $10.64 million for the current quarter, according to Zacks. Five analysts have provided estimates for Merus’ earnings, with the highest sales estimate coming in at $11.77 million and the lowest estimate coming in at $7.90 million. Merus reported sales of $12.38 million in the same quarter last year, which indicates a negative year over year growth rate of 14.1%. The company is expected to report its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Merus will report full-year sales of $46.21 million for the current fiscal year, with estimates ranging from $35.40 million to $52.70 million. For the next year, analysts expect that the firm will post sales of $63.25 million, with estimates ranging from $37.95 million to $137.15 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for Merus.

Merus (NASDAQ:MRUSGet Rating) last released its quarterly earnings data on Monday, February 28th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.24. Merus had a negative net margin of 143.77% and a negative return on equity of 29.02%. The company had revenue of $14.71 million during the quarter, compared to the consensus estimate of $12.39 million.

Several equities analysts recently commented on MRUS shares. HC Wainwright reissued a “buy” rating on shares of Merus in a research report on Tuesday, May 10th. Citigroup reduced their target price on shares of Merus from $38.00 to $37.00 and set a “buy” rating on the stock in a research report on Thursday. Zacks Investment Research upgraded shares of Merus from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a research note on Friday, May 13th. BMO Capital Markets began coverage on shares of Merus in a research note on Friday, February 11th. They set an “outperform” rating and a $45.00 price target on the stock. Finally, StockNews.com assumed coverage on shares of Merus in a research report on Thursday, March 31st. They issued a “hold” rating for the company. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $37.67.

In other Merus news, EVP Peter B. Silverman sold 60,000 shares of Merus stock in a transaction that occurred on Thursday, March 10th. The stock was sold at an average price of $26.95, for a total value of $1,617,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 2.90% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Merus during the fourth quarter valued at approximately $58,000. Lazard Asset Management LLC bought a new stake in shares of Merus during the first quarter valued at approximately $58,000. Macquarie Group Ltd. raised its holdings in shares of Merus by 104.5% during the third quarter. Macquarie Group Ltd. now owns 2,585 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 1,321 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Merus by 53.9% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,825 shares of the biotechnology company’s stock valued at $75,000 after buying an additional 989 shares during the last quarter. Finally, UBS Group AG raised its holdings in shares of Merus by 15.8% during the third quarter. UBS Group AG now owns 3,299 shares of the biotechnology company’s stock valued at $72,000 after buying an additional 449 shares during the last quarter. 85.32% of the stock is currently owned by institutional investors.

Shares of NASDAQ MRUS opened at $16.80 on Friday. Merus has a 1-year low of $14.78 and a 1-year high of $33.09. The company has a market capitalization of $731.64 million, a price-to-earnings ratio of -8.98 and a beta of 1.11. The business has a 50-day moving average of $23.25 and a 200-day moving average of $26.12.

Merus Company Profile (Get Rating)

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.

Recommended Stories

Get a free copy of the Zacks research report on Merus (MRUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Merus (NASDAQ:MRUS)

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.